Back to Search
Start Over
Supplementary Data from A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Data from A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....1edb380ecd1bb3a3d55383731ac57703
- Full Text :
- https://doi.org/10.1158/1078-0432.22487289